Antithrombin Therapy During Percutaneous Coronary Intervention (PCI) (patient information)
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cardiology Network |
 Discuss Antithrombin Therapy During Percutaneous Coronary Intervention (PCI) (patient information) further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
IV unfractionated heparin is the most common anticoagulant used in the cath lab.
Mechanism of action
Heparin is a glycosaminoglycan of 12-15 kDa that binds Anti-Thrombin 3 and facilitates its ability to inhibit coagulation factors 2a(thrombin) and 10a by a factor of 1000. Thrombin plays a central role not only in plasma coagulation (by catalyzing fibriongen to fibrin as well as activating several coagulation factors) but platelet activation as well.
Advantages
- familiarity with use
- level of anticoagulation can be titrated with ACT. Target ACT typically 200-250 with 2b/3a
and 250-350 without 2b/3a (these levels have been empirically derived and target ACT's have fallen in the stent era as the risk for acute vessel closure has diminished)
- Can be reversed with protamine (1mg of protamine for 100u of heparin acutely) in case of coronary artery perforation or vascular access complication.
- No dose adjustment needed for renal dysfunction
- Inexpensive
Disadvantages
- significant protein binding
- monitoring required as level of anticoagulation varies widely between patients
- inability to inactive clot-bound thrombin
- does not prevent the platelet activation of thrombin
- risk of HIT- Heparin Induced Thrombocytopenia
LMWH
Mechanism of Action
Formed by cleavage of UFH molecules to derive compounds 1/3 the size. This shorter molecule does not bind AT3 and Thrombin well but can bind AT 3 to Factor 10a. The most used LMWH Enoxaparin (Lovenox) has a 10a/2a ratio of 3.8.
Advantages
- longer half life so can be given SQ instead of IV continuous infusion. However, depending on when last dose of SQ heparin given, may need to give small booster dose of IV Lovenox prior to PCI.
- less protein binding and much lower incidence of HIT
- several trials have shown lower rates of ischemic complications in spectrum of ACS (not just pts treated invasively) as compared to Heparin (STEMI trials ENTIRE/TIMI 23, CREATE, ExTRACT TIMI 25). Advantage less clear for NSTEMI/UA managed with early invasive strategy with recent large SYNERGY TRIAL failing to meet primary end point. However a meta-analysis by Murphy et al. EHJ 2007 showed decrease in MI at 8% vs 9.1% favoring LMWH. In recent PCI-ExTRACT trial (the 4676 pts out of 20,479 in ExTRACT-TIMI 25 who underwent angioplasty after fibrinolysis) there was reduction in death or reinfarction at 30 days of 10.7% vs 13.8% P=.001 with no excess bleeding and fewer strokes.
Disadvantages
- more difficult to reverse than Heparin.
- although dosing more reliable than Heparin, without a monitoring system it can be difficult to dose appropriately for pts that are elderly, morbidly obese, or have renal insufficiency
- no clear advantage in elective PCI over Heparin in reducing ischemic complications but may reduce bleeding (CRUISE n=261 and STEEPLE n=3528) in selected populations
- when pts receive LMWH prior to cath and then UFH at time of PCI (switching) their bleeding complications increase significantly (SYNERGY and OASIS-5)
Summary
- Lovenox likely better choice in pts with STEMI especially if they are initially treated with lytics as long as they are not aged, morbidly obese, or have renal insufficiency.
LMWH likely better choice than heparin in pts with UA/NSTEMI initially managed medically/conservatively. Lovenox reasonable choice in elective PCI especially if radial approach used.
Dosing
as no monitoring, the dosing of Lovenox can be more difficult.
If given SQ therapeutic anticoagulation is reached by 60 minutes. With a half life or around 6 hours the level of anticoagulation can wane if PCI is done several hours after last dose.
- If last SQ lovenox given less than 8 hrs ago proceed to PCI
- If last SQ lovenox given 8-12 hrs ago rebolus with .3mg/kg
- If last SQ lovenox given more than 12 hrs ago rebolus with .75mg/kg
When switching from lovenox to heparin per SYNERGY trial
- If last SQ lovenox given less than 8 hrs ago no heparin bolus start drip at 12 u/hr
- If last SQ lovenox given 8-12 hrs ago give half bolus (30u/kg) then start drip
- If last SQ lovenox given more than 12 hrs ago give full bolus then start drip
Direct thrombin inhibitors
Mechanism of action
Unlike UFH or LMWH, Direct Thrombin inhibitors (Lepirudin, Argatroban and Bivalirudin), don't require the help of AT-3 to exert their anticoagulation effect. These medicines are IV only, but there is great interest in developing safe oral DTI to replace coumadin in the DVT/PE and Afib population. Bivalirudin (Angiomax) is the only DTI used commonly in the cath lab although the others have been studied.
Advantages
- Short Half life. This facilitates early sheath removal after PCI (and makes interventional fellows happy)
- Can inhibit fibrin-bound thrombin
- Easy dosing regimen. Can be adjusted for patients with renal insufficiency.
- Fewer bleeding complications especially at access site. This advantage increases as bleeding risk increases due to age and renal insufficiency.
- Best regimen for patients with known HIT.
Disadvantages
- cost (however this is offset if use of bival obviates need for 2b/3a)
- no benefit over heparin if a 2b/3a needs to be added.
Trials with BIVALIRUDIN
Replace 2-Compared Bivalirudin plus provisional 2b/3a (which ended up being given in 7.2% of pts) vs heparin with planned 2b/3a. In this study of 6010 pts ischemic events were similar but major bleeding (mostly vascular access site) was reduced by about 40%. There was no mortality difference at one year despite a .8% absolute increase in peri-procedural MI's in the bivalirudin group. Importanly 85% of pts were pre-treated with plavix or ticlid. In Replace 2 Bival strategy found to be less expensive because of savings on 2b/3a as well as less bleeding
Acuity
Complex trial of 13,819 high risk UA or NSTEMI pts undergoing early invasive strategy comparing Bivalirudin alone vs Bivalirudin with 2b/3a vs Heparin or Lovenox with 2b/3a. Found the ischemic composite endpoint (death, MI, revasc) at 30 days to be the same in all 3 arms. However, major bleeding was significantly less with Bival alone at 3.1% vs Bival+2b3a at 5.3% and Heparin/Lovenox+2b3a at 5.7%. Again this was driven mostly by access site complications, but unlike in REPLACE 2 the bleeding endpts were significant whether one used the study definition or TIMI definition. A major caveat is also that pts who did not get plavix had increased ischemic events in the bival only arm.
Conclusion
Bivalirudin is a excellent choice in most NSTEMI/UA pts managed with an early invasive strategy if they have been pre-treated with plavix. If this has not been done then 2b/3a will need to be used and the benefits of bivalirudin are greatly attenuated.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
